Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 62

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties

Song, Huaxin, Wu, Jiale, Tang, Yigang, Dai, Yuting, Xiang, Xinrong, Li, Ya, Wu, Lili, Wu, Jiaqi, Liang, Ying, Xing, Yangfei, Yan, Ni, Li, Yuntong, Wang, Zhengyuan, Xiao, Shujun, Li, Jiabing, Zheng, Derun, Chen, Xinjie, Fang, Hai, Ye, Chenjing, Ma, Yuting, Wu, Yu, Wu, Wen, Li, Junming, Zhang, Sujiang, Lu, Min·2023·Science Translational Medicine
DOI 10.1126/scitranslmed.abn9155
Open this paper in CoChat — free account

Abstract

Tumor suppressor p53 is inactivated by thousands of heterogeneous mutations in cancer, but their individual druggability remains largely elusive. Here, we evaluated 800 common p53 mutants for their rescue potencies by the representative generic rescue compound arsenic trioxide (ATO) in terms of transactivation activity, cell growth inhibition, and mouse tumor–suppressive activities. The rescue potencies were mainly determined by the solvent accessibility of the mutated residue, a key factor determining whether a mutation is a structural one, and the temperature sensitivity, the ability to reassemble the wild-type DNA binding surface at a low temperature, of the mutant protein. A total of 390 p53 mutants were rescued to varying degrees and thus were termed as type 1, type 2a, and type 2b mutations, depending on the degree to which they were rescued. The 33 type 1 mutations were rescued to amounts comparable to the wild type. In PDX mouse trials, ATO preferentially inhibited growth of tumors harboring type 1 and type 2a mutants. In an ATO clinical trial, we report the first-in-human mutant p53 reactivation in a patient harboring the type 1 V272M mutant. In 47 cell lines derived from 10 cancer types, ATO preferentially and effectively rescued type 1 and type 2a mutants, supporting the broad applicability of ATO in rescuing mutant p53. Our study provides the scientific and clinical communities with a resource of the druggabilities of numerous p53 mutations ( www.rescuep53.net ) and proposes a conceptual p53-targeting strategy based on individual mutant alleles rather than mutation type.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abn9155

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 52

  1. 10.1056/NEJMsb1607705 · DOI · Paper page
  2. 10.1038/537S63a · DOI · Paper page
  3. 10.1038/nature12634 · DOI · Paper page
  4. 10.1002/humu.23035 · DOI · Paper page
  5. 10.1038/sj.onc.1210291 · DOI · Paper page
  6. 10.1073/pnas.0607286103 · DOI · Paper page
  7. 10.1101/gad.190678.112 · DOI · Paper page
  8. 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
  9. 10.3389/fonc.2015.00288 · DOI · Paper page
  10. 10.1016/j.ccell.2020.11.013 · DOI · Paper page
  11. 10.1016/j.ccr.2012.03.042 · DOI · Paper page
  12. 10.7554/eLife.61487 · DOI · Paper page
  13. 10.18632/oncotarget.2432 · DOI · Paper page
  14. 10.1200/JCO.20.02342 · DOI · Paper page
  15. D. A. Sallman, A. E. DeZern, G. Garcia-Manero, D. P. Steensma, G. J. Roboz, M. A. Sekeres, T. Cluzeau, K. L. Sweet, A. McLemore, K. L. McGraw, J. Puskas, L. Zhang, J. Yao, Q. Mo, L. Nardelli, N. H. Al Ali, E. Padron, G. Korbel, E. C. Attar, H. M. Kantarjian, J. E. Lancet, P. Fenaux, A. F. List, R. S. Komrokji, Eprenetapopt (APR-246) and azacitidine inTP53-mutant myelodysplastic Syndromes. Clin. Oncol. 39, 1584–1594 (2021).
  16. 10.1016/j.xpro.2021.100688 · DOI
  17. 10.1073/pnas.1431692100 · DOI · Paper page
  18. 10.1016/j.molcel.2018.06.012 · DOI · Paper page
  19. 10.1093/nar/gkj518 · DOI · Paper page
  20. 10.1006/scbi.1998.0094 · DOI
  21. 10.1038/nrc3711 · DOI · Paper page
  22. E. S. Stavridi Y. Huyen E. A. Sheston T. D. Halazonetis in The p53 Tumor Suppressor Pathway and Cancer G. P. Zambetti Ed. (Springer US 2005) pp. 25–52.
  23. 10.1016/j.molcel.2006.05.015 · DOI · Paper page
  24. 10.1038/sj.onc.1204316 · DOI
  25. 10.1016/0022-2836(92)90386-X · DOI
  26. 10.1038/sj.onc.1203434 · DOI · Paper page
  27. 10.1038/onc.2016.502 · DOI · Paper page
  28. 10.1186/s12885-019-5907-7 · DOI · Paper page
  29. 10.1038/s41568-020-0290-x · DOI · Paper page
  30. 10.1182/blood-2011-05-354530 · DOI
  31. 10.1073/pnas.2003900117 · DOI
  32. 10.1038/s41421-020-00223-4 · DOI
  33. 10.1007/s00228-002-0514-x · doi:10.1007/s00228-002-0514-x
  34. 10.1182/blood-2015-03-580027 · DOI · Paper page
  35. 10.1182/blood-2017-09-801498 · DOI · Paper page
  36. 10.3390/biom9110668 · DOI
  37. 10.1002/cncr.21925 · doi:10.1002/cncr.21925
  38. 10.1002/cncr.21386 · DOI
  39. 10.1186/s12967-016-0861-5 · DOI
  40. 10.1158/1541-7786.MCR-10-0534 · DOI · Paper page
  41. 10.1371/journal.pone.0051426 · DOI · Paper page
  42. 10.1101/gad.1662908 · DOI · Paper page
  43. 10.1038/35094077 · DOI · Paper page
  44. 10.1038/s41586-021-03898-1 · DOI · Paper page
  45. 10.1002/humu.10032 · DOI
  46. 10.1534/genetics.104.039107 · DOI · Paper page
  47. W. Cleveland E. Grosse W. Shyu Local Regression Models. Chapter 8 in Statistical Models in S J. M. Chambers T. J. Hastie Eds. (Wadsworth & Brooks/Cole 1992) 608 p..
  48. 10.1038/nbt.4096 · DOI · Paper page
  49. 10.1038/s41592-019-0619-0 · DOI · Paper page
  50. 10.1038/nbt.4314 · DOI · Paper page
  51. 10.1038/nmeth.4150 · DOI · Paper page
  52. Q. Mao L. Wang S. Goodison Y. Sun Dimensionality reduction via graph structure learning in Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (Association for Computing Machinery 2015) pp. 765–774. · DOI

Cited by

See all 62

Metadata

Authors
Song, H., Wu, J., Tang, Y., Dai, Y., Xiang, X., Li, Y., Wu, L., Wu, J., Liang, Y., Xing, Y., Yan, N., Li, Y., Wang, Z., Xiao, S., Li, J., Zheng, D., Chen, X., Fang, H., Ye, C., Ma, Y., Wu, Y., Wu, W., Li, J., Zhang, S., & Lu, M.
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2023-04-05
Volume
15
Issue
690
ISSN
  • 1946-6234
  • 1946-6242
DOI
10.1126/scitranslmed.abn9155
Cited by
62
References
15
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. https://app.cochat.ai/papers/10.1126/scitranslmed.abn9155
The paper
Song, H., Wu, J., Tang, Y., Dai, Y., Xiang, X., Li, Y., Wu, L., Wu, J., Liang, Y., Xing, Y., Yan, N., Li, Y., Wang, Z., Xiao, S., Li, J., Zheng, D., Chen, X., Fang, H., Ye, C., . . . Lu, M. (2023). Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abn9155

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.